Glenmark Pharmaceuticals gains as its arm launches Winlevi across key markets in Europe
Glenmark Pharmaceuticals is currently trading at Rs. 2152.00, up by 7.90 points or 0.37% from its previous closing of Rs. 2144.10 on the BSE.
The scrip opened at Rs. 2144.00 and has touched a high and low of Rs. 2160.00 and Rs. 2142.00 respectively. So far 5927 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1594.45 on 11-Jun-2025.
Last one week high and low of the scrip stood at Rs. 2,432.20 and Rs. 2132.80 respectively. The current market cap of the company is Rs. 60633.67 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.67% and 13.68% respectively.
Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Specialty S.A (GSSA) has launched Winlevi (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (Cosmo) in October 2025.
Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the company has launched the product through a strategic partner. Glenmark is also advancing additional launches through strategic partnerships across other European markets. The product is authorized in the European Union for the treatment of acne vulgaris in adults and adolescents. The product has been developed by Cassiopea, which holds rights across Europe and collaborates with regional partners for commercialization. Acne vulgaris is one of the most common dermatological conditions globally.
Winlevi is the first topical acne therapy in more than 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgenreceptor inhibitor acting locally in the sebaceous glands to reduce sebum production and inflammation without systemic anti-androgen effects, supporting safe use in both males and females. The availability of the product represents an additional treatment option for healthcare professionals and patients in Europe.
